Vaccine manufacturer Bharat Biotech International Limited (BBIL) is making a foray into the cell and gene therapy (CGT) space ...

Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority ...

Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

"“The 24/25 Cup Kit is a tribute to Borussia Dortmund’s rich history and the moments that have shaped the Club. We aimed to ...

Cancer isn’t just one disease, but many — each with its own challenges, characteristics, risks and treatments. As we have ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an ...

T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before ...

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...